Phase II Study of Axitinib (AG-013736) with Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma

Protocol: 
AAAR5314
Phase: 
II

Phase II Study of Axitinib (AG-013736) with Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma

Axitinib (AG-013736) is an investigational (experimental) drug that is being
studied in patients with metastatic pheochromocytoma/paraganglioma. The main
goal of this study is to find out if axitinib is able to stop tumors from
growing, or shrink tumors in patients with this type of cancer.

Are you Eligible? (Inclusion Criteria)

-Age ≥ 18 years
-A life expectancy of at least 3 months
-ECOG performance status ≤ 2

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States